Outcomes in COVID-19 antroquinonol studies

0 0.5 1 1.5+ All studies -200% 1 124 Improvement, Studies, Patients Relative Risk Hospitalization 2% 1 122 Viral clearance 7% 1 124 RCTs -200% 1 124 Late -200% 1 124 Antroquinonol for COVID-19 c19early.org November 2025 Favorsantroquinonol Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) -200% 3.00 [0.12-72.3] progression 1/62 0/62 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Late treatment -200% 3.00 [0.12-72.3] 1/62 0/62 200% higher risk All studies -200% 3.00 [0.12-72.3] 1/62 0/62 200% higher risk 1 antroquinonol COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors antroquinonol Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) 2% 0.98 [0.75-1.30] hosp. time 60 (n) 62 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.92 Late treatment 2% 0.98 [0.75-1.30] 60 (n) 62 (n) 2% lower risk All studies 2% 0.98 [0.75-1.30] 60 (n) 62 (n) 2% lower risk 1 antroquinonol COVID-19 hospitalization result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.92 Favors antroquinonol Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) -200% 3.00 [0.12-72.3] progression 1/62 0/62 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Late treatment -200% 3.00 [0.12-72.3] 1/62 0/62 200% higher risk All studies -200% 3.00 [0.12-72.3] 1/62 0/62 200% higher risk 1 antroquinonol COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors antroquinonol Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) -17% 1.17 [0.53-2.58] recov. time 62 (n) 62 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.72 Late treatment -17% 1.17 [0.53-2.58] 62 (n) 62 (n) 17% higher risk All studies -17% 1.17 [0.53-2.58] 62 (n) 62 (n) 17% higher risk 1 antroquinonol COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.72 Favors antroquinonol Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) 7% 0.93 [0.43-2.00] viral time 62 (n) 62 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Late treatment 7% 0.93 [0.43-2.00] 62 (n) 62 (n) 7% lower risk All studies 7% 0.93 [0.43-2.00] 62 (n) 62 (n) 7% lower risk 1 antroquinonol COVID-19 viral clearance result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Favors antroquinonol Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) -200% 3.00 [0.12-72.3] progression 1/62 0/62 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Late treatment -200% 3.00 [0.12-72.3] 1/62 0/62 200% higher risk All studies -200% 3.00 [0.12-72.3] 1/62 0/62 200% higher risk 1 antroquinonol COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors antroquinonol Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) -200% 3.00 [0.12-72.3] progression 1/62 0/62 Improvement, RR [CI] Treatment Control Cheng (DB RCT) -17% 1.17 [0.53-2.58] recov. time 62 (n) 62 (n) Cheng (DB RCT) 6% 0.94 [0.77-1.14] recov. time 62 (n) 62 (n) Cheng (DB RCT) 2% 0.98 [0.75-1.30] hosp. time 60 (n) 62 (n) Cheng (DB RCT) 7% 0.93 [0.43-2.00] viral time 62 (n) 62 (n) Antroquinonol COVID-19 outcomes c19early.org November 2025 Favors antroquinonol Favors control